Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Short Interest Up 21.5% in December

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 2,413,847 shares, a growth of 21.5% from the December 15th total of 1,986,266 shares. Approximately 4.3% of the shares of the company are short sold. Based on an average daily trading volume, of 347,089 shares, the days-to-cover ratio is presently 7.0 days. Based on an average daily trading volume, of 347,089 shares, the days-to-cover ratio is presently 7.0 days. Approximately 4.3% of the shares of the company are short sold.

Kestra Medical Technologies Price Performance

NASDAQ KMTS traded up $0.15 on Tuesday, reaching $23.00. The company’s stock had a trading volume of 151,823 shares, compared to its average volume of 280,194. Kestra Medical Technologies has a twelve month low of $13.25 and a twelve month high of $30.00. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.47 and a current ratio of 5.47. The firm’s 50 day moving average is $25.63 and its two-hundred day moving average is $22.16. The stock has a market cap of $1.34 billion and a PE ratio of -7.26.

Wall Street Analysts Forecast Growth

KMTS has been the topic of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Wells Fargo & Company lifted their price objective on shares of Kestra Medical Technologies from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Wall Street Zen lowered shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Sunday, September 28th. The Goldman Sachs Group set a $24.00 price target on shares of Kestra Medical Technologies in a research report on Friday. Finally, BTIG Research began coverage on shares of Kestra Medical Technologies in a research note on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price target for the company. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.00.

Insider Buying and Selling at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Traci S. Umberger sold 10,500 shares of the business’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $26.69, for a total transaction of $280,245.00. Following the completion of the transaction, the insider directly owned 136,633 shares of the company’s stock, valued at $3,646,734.77. The trade was a 7.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Brian Daniel Webster sold 15,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $22.80, for a total transaction of $342,000.00. Following the completion of the transaction, the insider owned 394,786 shares of the company’s stock, valued at approximately $9,001,120.80. This trade represents a 3.66% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 40,500 shares of company stock valued at $1,021,095. Corporate insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of KMTS. Alliancebernstein L.P. boosted its stake in shares of Kestra Medical Technologies by 13.7% during the 3rd quarter. Alliancebernstein L.P. now owns 1,491,970 shares of the company’s stock worth $35,449,000 after acquiring an additional 179,885 shares in the last quarter. Eventide Asset Management LLC boosted its position in shares of Kestra Medical Technologies by 285.7% in the 2nd quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company’s stock valued at $17,584,000 after purchasing an additional 785,557 shares during the period. Brown Advisory Inc. increased its stake in Kestra Medical Technologies by 5.4% in the 2nd quarter. Brown Advisory Inc. now owns 580,025 shares of the company’s stock worth $9,617,000 after purchasing an additional 29,607 shares in the last quarter. Millennium Management LLC acquired a new stake in Kestra Medical Technologies during the 1st quarter worth about $11,036,000. Finally, Franklin Resources Inc. lifted its stake in Kestra Medical Technologies by 32.4% during the second quarter. Franklin Resources Inc. now owns 441,398 shares of the company’s stock valued at $7,318,000 after buying an additional 108,103 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.